Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Eternity Bioscience

Next Previous
Search
Drug Profile

Research programme: cancer therapeutics - Eternity Bioscience

Alternative Names: Anaplastic lymphoma kinase inhibitors - Eternity Bioscience; BRAF inhibitors - Eternity Bioscience; BTK inhibitors - Eternity Bioscience; EBI 1041; EBI-1051; EBI-1266; EBI-1367; EBI-907; EBI-945; MEK1 inhibitors - Eternity Bioscience; PARP-1/2 inhibitors - Eternity Bioscience; SHR-1266; TG-1702

Latest Information Update: 28 Jul 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eternity Bioscience
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Enhancer of zeste homolog 2 protein inhibitors; MAP kinase kinase 1 inhibitors; Poly(ADP-ribose) polymerase inhibitors; Proto-oncogene protein b-raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Breast cancer; Cancer; Ovarian cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Breast-cancer in USA (PO)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top